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Abstract
Background: The ability of transfected synthetic small interfering (si) RNAs to suppress the
expression of specific transcripts has proved a useful technique to probe gene function in
mammalian cells. However, high production costs limit this technology's utility for many
laboratories and experimental situations. Recently, several DNA-based plasmid vectors have been
developed that direct transcription of small hairpin RNAs, which are processed into functional
siRNAs by cellular enzymes. Although these vectors provide certain advantages over chemically
synthesized siRNAs, numerous disadvantages remain including merely transient siRNA expression
and low and variable transfection efficiency.
Results: To overcome several limitations of plasmid-based siRNA, a retroviral siRNA delivery
system was developed based on commerically available vectors. As a pilot study, a vector was
designed to target the human Nuclear Dbf2-Related (NDR) kinase. Cells infected with the anti-
NDR siRNA virus dramatically downregulate NDR expression, whereas control viruses have no
effect on total NDR levels. To confirm and extend these findings, an additional virus was
constructed to target a second gene, transcriptional coactivator p75.
Conclusion: The experiments presented here demonstrate that retroviruses are efficient vectors
for delivery of siRNA into mammalian cells. Retrovirus-delivered siRNA provides significant
advancement over previously available methods by providing efficient, uniform delivery and
immediate selection of stable "knock-down" cells. This development should provide a method to
rapidly assess gene function in established cell lines, primary cells, or animals.
Background
RNA interference (RNAi) is a phenomenon describing
double-stranded (ds)RNA-dependent gene specific post-
transcriptional silencing. Initial attempts to harness this
phenomenon for experimental manipulation of mamma-
lian cells were foiled by a robust and nonspecific antiviral
defense mechanism activated in response to long dsRNA
molecules [1]. The field was significantly advanced upon
the demonstration that synthetic duplexes of 21 nucle-
otide RNAs could mediate gene specific RNAi in mamma-
lian cells, without invoking generic antiviral defense
mechanisms [2,3]. As a result, siRNAs have become pow-
erful tools to dissect gene function. Unfortunately, the
chemical synthesis of small RNAs is prohibitively expen-
sive for numerous laboratories and experimental situa-
tions. Consequently, numerous groups have sought the
development of DNA-based vectors capable of generating
such siRNA within cells. Several groups have recently at-
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tained this goal and published similar strategies that, in
general, involve transcription of short hairpin (sh)RNAs
that are efficiently processed to form siRNAs within cells
[4–7]. These reports describe intricate (and ingenious)
methods to generate siRNAs capable of specifically target-
ing numerous endogenously and exogenously expressed
genes. With time, these substantial advances will un-
doubtedly provide critical insight into gene function.
Despite the advantages of these new plasmid vectors, nu-
merous shortcomings remain. In particular, the expres-
sion of the siRNA is transient and, like any other plasmid,
the transfection efficiency is often low and inconsistent.
Therefore, we sought to develop a more tractable and effi-
cient siRNA delivery system. The following brief report de-
scribes a method to incorporate the PolIII-transcribed
small hairpin system into a retroviral vector. Our results
suggest retroviruses will be extremely useful delivery vehi-
cles for siRNA expression in mammalian cells.
Results
Development of a retroviral siRNA delivery vector
Recently, several DNA-based RNAi vectors have become
available [4–7]. We initially employed the pBS/U6 vector
(now sold as pSilencer 1.0-U6, available from Ambion,
Austin, TX) which contains the RNA PolIII-specific U6
gene promoter along with restriction sites convenient for
oligonucleotide insertion. [6]. We chose to target a poorly
defined human serine-threonine kinase, Nuclear Dbf-2
Related (NDR). Oligonucleotides targeting a region of
NDR were cloned into the pBS/U6 vector to generate pBS/
U6-NDR. When HeLa cells were transiently transfected
with pBS/U6-NDR, no noticeable decrease in NDR expres-
sion was detectable by western blot (data not shown). In-
terpretation of the above experiment was complicated due
to the relatively high number of untransfected HeLa cells
still expressing normal levels of NDR.
Figure 1
Construction of retroviral siRNA delivery vector Schematic of genome structure. All plasmids were derived from
pMSCVpuro (Clontech). The inserted U6 promoter is illustrated in blue, while the control and anti-NDR hairpins are shown in
red and green, respectively. Ψ +, extended packaging signal. MCS, multiple cloning site. PGK, murine phosphoglycerate kinase
promoter. Puror, puromycin resistance gene. N/B and B/N, cloning junction generated by ligating the blunt ended BamHI and
NsiI restriction sites.
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To circumvent the problems associated with transient
transfections, a retroviral siRNA vector was developed. As
illustrated in Figure 1, the U6 promoter and anti-NDR
hairpin was subcloned from pBS/U6-NDR into pM-
SCVpuro (Clontech, Palo Alto, CA) at the unique NsiI site
just upstream from the 3' LTR. Retroviral vectors contain-
ing only the U6 promoter (pMSCV/U6) or containing the
U6 promoter plus an irrevelant hairpin (pMSCV/U6-cont)
were also constructed.
Stable, efficient inhibition of NDR by retrovirus-delivered 
siRNA
HeLa cells were mock-infected or infected with
MSCVpuro, MSCV/U6, MSCV/U6-cont, or MSCV/U6-
NDR. Twenty-four hours after infection, infected cells
were selected in media containing puromycin. After a sin-
gle day of selection, all mock-transfected cells died, where-
as nearly all cells infected with MSCV, MSCV/U6, MSCV/
U6-cont, or MSCV/U6-NDR survived and proliferated.
These results indicate that insertion of the U6 promoter
upstream of the 3' LTR has no noticeable effects on virus
packaging or infectivity. After expanding the infected cell
population, a fraction of the cells were lysed for western
blot analysis. An equal amount of total protein was frac-
tionated by SDS-PAGE and probed with monoclonal an-
tibodies to NDR (~54 KDa) and an unrelated protein
(p75) as a loading and specificity control (Fig. 2). The
western blot demonstrates that a dramatic downregula-
tion of NDR occurs following infection with MSCV/U6-
NDR but is unchanged upon infection with control virus-
es. Cells lysed 24 hours post-infection (ie., without selec-
tion) gave identical results, indicating the integrated
virions induce rapid NDR silencing (data not shown). The
HeLa population infected with MSCV/U6-NDR has main-
tained NDR silencing after several passages (data not
shown).
Stable, efficient inhibition of p75 by retrovirus-delivered 
siRNA
We next sought to confirm and extend the above findings
by generating a retrovirus targeting an additional gene,
transcriptional coactivator p75. HeLa cells obtained from
an alternative source (in this case, HeLa-CD4 cells) were
infected and selected essentially as described above. West-
ern blot analysis demonstrates a remarkable downregula-
tion of p75 occurs specifically in cells infected with
MSCV/U6-p75 (Fig. 3). Likewise, levels of NDR are dra-
matically reduced in cells infected with MSCV/U6-NDR
(Fig. 3).
Discussion
Several strategies to express siRNA via DNA-based plas-
mids have recently become available. While these plas-
mids provide a significant advantage over synthetic RNAs,
several disadvantages remain, including all of the well-
known difficulties involving transient transfections (low
efficiency, uneven distribution, high variability, etc.). As a
result, determining the effectiveness of a particular vector
is not a trivial endeavour, particular since the "effect" may
be a modest gene downregulation within a small fraction
of total cells. Moreover, with both synthetic siRNA and
plasmid-based vectors, the siRNA expression is transient.
Selection of stable clones has been demonstrated with
plasmid vectors, although this process requires several
Figure 2
Rapid, stable suppresion of NDR by retrovirus-deliv-
ered siRNA HeLa cells were infected with the viruses illus-
trated in Fig. 1. Proteins were extracted from cells infected
with each virus and NDR levels were examined by western
blot analysis. Arrow indicates dramatic downregulation of
NDR only in cells infected with MSCV/U6-NDR. The upper
band was detected by the anti-p75 antibody, which serves as
an internal loading and specificity control. Identical results
were obtained with cells examined 24-hours post infection
or after several passages (data not shown).
Figure 3
Suppression of NDR and p75 expression by retrovi-
rus-delivered siRNA. HeLa-CD4 cells were infected the
viruses illustrated in Fig. 1 plus an additional virus, MSCV/U6-
p75. Western blot analysis demonstrates a dramatic down-
regulation of p75 in cells infected with MSCV/U6-p75 and
NDR in cells infected with MSCV/U6-NDR. Infection with
the various control viruses (MSCV, MSCV/U6, or MSCV/U6-
cont) had no effect on p75 or NDR levels. For the mock-
infected sample, puromycin selection was omitted.BMC Biotechnology 2002, 2 http://www.biomedcentral.com/1472-6750/2/15
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weeks or months and is ultimately problematic due to po-
tential clonal effects.
To overcome these problems, we sought to incorporate
the key elements of the well-defined pBS/U6 siRNA vector
into a retrovirus. Data presented in this report indicate
that retroviruses are suitable vectors to deliver siRNAs to
mammalian cells. Given the simplicity of this system,
which employs readily available reagents, any laboratory
should be able to initiate a retroviral siRNA project. We
have identified a viable insertion site for an RNA PolIII
promoter and oligonucleotide hairpin into a retrovirus
that does not noticeably affect packaging or infectivity. By
inserting the U6 promoter/hairpin at this site, we have
preserved the multiple cloning site (MCS) of pMSCVpuro
(Fig 1), which could allow insertion of an additional gene
of interest for knock-in/knock-down experiments. Using
this strategy, we have generated retroviruses that efficient-
ly downregulate the expression of the protein kinase NDR
and the transcriptional coactivator p75 by RNAi. The sta-
ble propagation of these cell lines demonstrates that
"wild-type" levels of NDR or p75 are not essential for
HeLa cell viability. It is worth noting that although the
levels of NDR and p75 are dramatically reduced following
infection with the respective viruses, the resultant cells
may not be true "knock-outs."
The methods described above involve initially subcloning
the hairpin into a transition vector (pBS/U6, now sold as
pSilencer 1.0-U6) prior to insertion into pMSCVpuro.
Slight modifications of pMSCVpuro (or pMSCV/U6 vec-
tor developed here) will allow single one-step cloning of
oligonucleotide duplexes. However, the initial cloning
step may prove useful in many cases, as it may provide
unique restriction sites for rapid insertion into other retro-
viral vectors containing convenient markers (i.e. alternate
antibiotic resistance markers, GFP) or other context-spe-
cific features (ie., knock-in Gene A, knock-down Gene B).
It is also enticing to envision retroviral-delivered regulata-
ble RNAi. Indeed, the U6 promoter has been successfully
modified by incorporation of tetracycline (Tet)-operator
sites [8]; this may prove useful when studying "essential"
genes. Once engineered into a retrovirus, this system
could be used to study early-stage events associated with
knocking-out a specific gene, such as changes in gene ex-
pression, protein localization, or cellular architecture.
Conclusions
The current work has combined two well-described and
commercially available systems. Our results demonstrate
that retroviruses are viable vectors for delivery of siRNAs.
This approach represents a dramatic improvement over
plasmid-based delivery systems, as retroviral infection is
rapid, uniform, and stable. The function of virtually any
gene can now be assayed in virtually any cell type, pre-
sumably including non-dividing primary cells if a lentivi-
rus packaging system is employed. Numerous
improvements to the present system can be envisioned,
some of which are highlighted above. As this technology
continues to evolve, researchers will be able to address
previously impenetrable questions in cell biology.
Methods
Construction of a retroviral vector for delivery of siRNA
The general strategy described for oligonucleotide inser-
tion into pBS/U6 [[6], Yang Shi, personal communica-
tion] was employed with some modification. Specifically,
the cloning was reduced to a single-step process, rather
than the piece-wise construction reported by Shi and col-
leagues. To generate pBS/U6-NDR, two oligonucleotides
were synthesized.
Oligo 1 (top-strand):
5'-GGACATGATGACCTTGTTGAaagcttTCAACAAGGT-
CATCATGTCCCTTTTTG-3'.
Oligo 2 (bottom strand):
5'-AATTCAAAAAGGGACATGATGACCTTGTTGAaagctt-
TCAACAAGGTCATCATGTCC-3'.
The first stretch of underlined nucleotides correspond to
nucleotides 515–535 of the NDR open reading frame (nu-
cleotides 1111–1130 of the NDR mRNA sequence, Gen-
Bank accession number NM_007271.). The lower case
letters represent a HindIII site. The second stretch of un-
derlined nucleotides is the reverse complement of the
first; transcribed RNA is therefore predicted to form a
small hairpin. The two oligonucleotides were annealed
and inserted into pBS/U6 digested with ApaI (and subse-
quently filled in with Klenow) and EcoRI. Clones contain-
ing the oligonucleotide insertion can be distinguished
from pBS/U6 by a diagnostic BamHI/XhoI digest (the
XhoI site present in the pBS/U6 MCS is lost upon inser-
tion of the oligonucleotide; clones with an oligonucle-
otide insert will thus liberate a larger BamHI-BamHI
fragment). Verification of the inserted sequence by auto-
mated DNA sequencing is not possible, presumably due
to the strong secondary structure associated with the short
hairpin. Inclusion of a larger "loop" (instead of the palin-
dromic HindIII sequence) could potentially overcome
this problem.
pBS/U6-NDR was digested with BamHI to liberate the U6
promoter and the oligonucleotide region complementary
to NDR. This BamHI-BamHI fragment was subsequently
blunt ended with Klenow and inserted into pMSCVpuro
(Clontech, Palo Alto, CA; vector sequence available at  [ht-
tp://www.clontech.com]) blunt ended at the unique NsiIBMC Biotechnology 2002, 2 http://www.biomedcentral.com/1472-6750/2/15
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site, generating pMSCV/U6-NDR. The BamHI-BamHI
fragment from pBS/U6, containing the U6 promoter and
MCS, was inserted into pMSCVpuro to generate pMSCV/
U6. An additional plasmid containing an irrelevant hair-
pin was similarly constructed to generate pMSCV/U6-
cont. For consistency, only plasmids with the U6 promot-
er pointing toward the 3' LTR were chosen for further
study (see Fig. 1). The above strategy was also used to gen-
erate pMSCV/U6-p75 with the following oligonucle-
otides:
Oligo 1 (top-strand):
5'-GGTCAAAGACTCTAAATGGAGaagcttCTCCATTTA-
GAGTCTTTGACCCTTTTTG-3'
Oligo 2 (bottom strand):
5'-aattcaaaaaGGGTCAAAGACTCTAAATGGAGaagcttCTC-
CATTTAGAGTCTTTGACC-3'
The underlined sequence corresponds to nucleotides
1420–1441 of the p75 open reading frame (GenBank ac-
cession number AF063020).
Viral packaging
pMSCVpuro, pMSCV/U6, pMSCV/U6-cont, or pMSCV/
U6-NDR were packaged in Pheonix Ampho cells (a kind
gift of G. Nolan, Standford University) by standard calci-
um phosphate transfection [9]. To improve titer, addi-
tional Gag-Pol and the VSV-G envelope was expressed by
cotransfection with PCG-gagpol and PCG-VSV-G (kind
gifts of Jonathon Walsh and Richard Mulligan, Harvard
Medical School). Virus supernatant was collected 48
hours post-transfection, pelleted to remove nonadherent
cells and cellular debris, frozen in small aliquots on dry
ice, and stored at -80 C.
HeLa cell infection and selection
Twenty-four hours prior to infection, HeLa cells (kind gift
of Tom Roberts, Harvard Medical School) were seeded at
20,000 cells per well in 24-well plates. The following day,
the culture media was aspirated and replaced with virus
supernatant diluted 1:2 (1 ml final) in growth media
(DMEM, 10% Fetal Bovine Serum, Penicillin-Streptomy-
cin). Polybrene was added to a final concentration of 4
ug/ml. 24 hours after infection, the cells were collected by
trypsinization and reseeded in 6 well dishes in selective
media (growth media + 1 ug/ml puromycin). By the next
day, all mock-infected cells were floating and presumably
dead or dying. Nearly all cells infected with MSCV-puro,
MSCV/U6, MSCV/U6-cont, or MSCV/U6-NDR adhered to
the wells and began to proliferate. In a subsequent exper-
iment, HeLa-CD4 cells (a kind gift of Alan Engelman, Har-
vard Medical School) were seeded at 200,000 cells per
well in a 6-well plate and infected with 2 ml of diluted
(1:2) virus supernatant. One day after infection, the cells
were collected and reseeded in 10-cm plates in selective
media. Virtually all of the cells subsequently adhered to
the new dish (with the exception of the mock control),
suggesting that viral titers were at least 2 ×  105/ml.
Protein extraction and western blot analysis
Protein was extracted in ice-cold cell lysis buffer (50 mM
Tris pH 7.5, 300 mM NaCl, 0.5% Triton X-100, 1 mM ED-
TA, Roche Complete Protease Inhibitor). Protein concen-
tration was determined using the BioRad DC Assay kit.
Fifteen µg of total protein was resolved by SDS-PAGE,
transferred to nitrocellulose, and probed with mono-
clonal anti-NDR and monoclonal anti-p75 (both from
Transduction Laboratories; Lexington, KY). Amido black
staining of the membrane further verified equivalent load-
ing and even electrotransfer (data not shown).
Authors' contributions
E.D. developed the retroviral siRNA system, performed
the described experiments, and drafted the manuscript.
P.S is the Prinicipal Investigator of the lab and participat-
ed in this study's design and development.
Acknowledgements
This work was supported by grants from the NIH and the Claudie Adams 
Barr Fund (P.S) and an HHMI Predoctoral Fellowship (E.D.). The authors 
wish to thank Yang Shi, Jonathon Walsh, and Richard Mulligan for plasmids, 
Gary Nolan for Pheonix Ampho cells, Tom Roberts for HeLa cells, Alan 
Engelman for HeLa-CD4 cells, and Alan Engelman and Guillaume Adelmant 
for insightful discussions.
References
1. Gil J, Esteban M: Induction of apoptosis by the dsRNA-depend-
ent protein kinase (PKR): Mechanisms of action.  Apoptosis
2000, 5:107-114
2. Elbashir S, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T:
Duplexes of 21-nucleotide RNAs mediate RNA interference
in cultured mammalian cells. Nature 2001, 411:494-498
3. Caplen N, Parrish S, Imani F, Fire A, Morgan R: Specific inhibition
of gene expression by small double-stranded RNAs in inver-
tebrate and vertebrate cells. Proc Natl Acad Sci 2001, 98:9742-
9747
4. Paddison P, Caudy A, Hannon G: Stable suppresion of gene ex-
pression by RNAi in mammalian cells. Proc Natl Acad Sci U S A
2002, 99:1443-1448
5. Paddison P, Caudy A, Bernstein E, Hannon G, Conklin D: Short hair-
pin RNAs (shRNAs) induce sequence-specific silencing in
mammalian cells. Genes & Dev 2002, 16:948-958
6. Sui G, Soohoo C, Affar E, Gay F, Shi Y, Forrester W, Shi Y: A DNA
vector-based RNAi technology to suppress gene expression
in mammalian cells. Proc Natl Acad Sci 2002, 8:5515-5520
7. Brummelkamp T, Bernards R, Agami R: A system for stable ex-
pression of short interfering RNAs in mammalian cells. Sci-
ence 2002, 296:550-553
8. Ohkawa J, Taira K: Control of the functional activity of an anti-
sense RNA by a tetracycline-responsive derivative of the hu-
man U6 snRNA promoter. Hum Gene Ther 2000, 11:577-585
9. Sambrook J, Fitsch EF, Maniatis T: Molecular Cloning: A Labora-
tory Manual. Cold Spring Harbor, Cold Spring Harbor Press 1989